Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:37 PM
Ignite Modification Date:
2025-12-24 @ 4:37 PM
NCT ID:
NCT00439166
Eligibility Criteria:
Inclusion Criteria:
* Male or female
* Age greater than or equal to 50 years
* Diagnosis of probable Alzheimer's disease by NINCDS-ADRDA criteria
* Standardized Mini-Mental State Examination score 14-26 inclusive
* A caregiver who consents to monitor study medications, report on patient function, bring the patient to visits, etc.
* Vision, hearing, language ability sufficient to complete standardized testing in English.
* Patient consents (or legal representative consents for patient)
* Generally stable level of health where patient may be reasonably expected to complete a 1 year trial
Exclusion Criteria:
* Other neurodegenerative diseases such as Lewy body or Parkinson's
* Cognitive impairment due to: acute trauma, subdural hematoma, hypoxic cerebral damage, B12 deficiency, infections such as AIDS or meningitis, cerebral neoplasia, endocrine deficiencies, mental retardation
* Significant cerebrovascular disease or multi-infarct dementia
* Intra-cranial pathology such as tumour
* Co-existing medical conditions such as epilepsy, major psychiatric conditions, depression (Cornell Depression in Dementia Scale score of 12 or more), significant liver, kidney, lung, metabolic or endocrine diseases
* Clinically significant cardiac disease such as uncontrolled angina or hypertension
* Anti-dementia treatments other than donepezil, galantamine, rivastigmine, memantine
* Enrollment in trials with other investigational drugs
* Antibiotic use more than one month in the last six months
* Allergy to doxycycline or rifampicin
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
50 Years
Study:
NCT00439166
Study Brief:
Protocol Section:
NCT00439166